Abstract
Parkinson’s disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.
Keywords: Alpha-synuclein, Immunization, Immunotherapy, Lewy Bodies, Parkinson's Disease, Toxins, Virus, SNpc, Alpha synuclein Fibrils, Dementia, Alzheimers disease, Active Immunization
CNS & Neurological Disorders - Drug Targets
Title:Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease
Volume: 11 Issue: 2
Author(s): Troy T. Rohn
Affiliation:
Keywords: Alpha-synuclein, Immunization, Immunotherapy, Lewy Bodies, Parkinson's Disease, Toxins, Virus, SNpc, Alpha synuclein Fibrils, Dementia, Alzheimers disease, Active Immunization
Abstract: Parkinson’s disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.
Export Options
About this article
Cite this article as:
Troy T. Rohn , Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269678
DOI https://dx.doi.org/10.2174/187152712800269678 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Neurobehavioral and Cognitive Changes Induced by Sleep Deprivation in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Editorial: US Students Alcohol Consumption: A Downward Trend, But Increased Concerns
Current Drug Abuse Reviews Medicinal Chemistry of Sirtuin Inhibitors
Current Medicinal Chemistry Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Synthesis and Biological Evaluation of Naloxone and Naltrexone-Derived Hybrid Opioids
Medicinal Chemistry The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Commentary (Brilliant Blue G: What a Little More Colour Can Be)
CNS & Neurological Disorders - Drug Targets Genetic Algorithm and Self-Organizing Maps for QSPR Study of Some N-aryl Derivatives as Butyrylcholinesterase Inhibitors
Current Drug Discovery Technologies Neuroimaging of Narcolepsy
CNS & Neurological Disorders - Drug Targets Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Current Pharmaceutical Design Diagnosis of Neurodegenerative Diseases: The Clinical Approach
Current Alzheimer Research